Redeye leaves a comment following Cinclus’ announcement that it has secured a structured growth-debt financing facility of up to EUR28m from Claret Capital Partners. The funding strengthens the company’s financial flexibility as it advances linaprazan glurate through late-stage development and prepares for the second part of its phase III program. We view the agreement as a constructive step that improves Cinclus’ strategic optionality ahead of its upcoming clinical milestones and potential partnering discussions.
LÄS MER
